The total global market for TAVR devices is expected to be worth $6.8bn in 2023 and reach $18.8bn in 2033. Credit: Shutterstock / ShutterOK.

The US Food and Drug Administration (FDA) has granted approval to Medtronic the its Evolut FX+ transcatheter aortic valve replacement (TAVR) system.

The device is designed for the treatment of symptomatic severe aortic stenosis.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to Medtronic, the Evolut FX+ system can offer increased coronary access windows through a modified diamond-shaped frame design, four times larger than previous designs.

It is the latest in Medtronic’s long-running TAVR range, a market in which a GlobalData market model estimates that Medtronic constitutes 33% of the US market at an estimated value of $561m. Sitting at second place behind Edwards Lifesciences 60.5% of the US market.

The total global market for TAVR devices is expected to be worth $6.8bn in 2023 and reach $18.8bn in 2033.

Severe aortic stenosis occurs when the aortic valve leaflets become stiff and have difficulty opening and closing, making the heart work harder to pump blood to the rest of the body.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Jeffrey Popma, chief medical officer for Medtronic’s structural heart and aortic business, said: “We are committed to consistently developing and advancing minimally invasive solutions for physicians to treat their patients with aortic stenosis.

“This is reinforced by our continued innovation of the Evolut TAVR platform, which has delivered proven valve performance and durability to physicians and patients for years. The Evolut FX+ TAVR system was designed to facilitate coronary access across a diverse range of patient anatomies with no compromise to valve performance.”

Besides TAVR devices, Medtronic is also a key player in the market of aortic guidewires where they are competing with US medtech company Boston Scientific. A market that GlobalData analysis predicts could become a key source of income as the rate of aortic stenosis procedures rises.

Elsewhere in the TAVR system market, Edwards Lifesciences has revealed positive data from two real-world studies evaluating its SAPIEN valve platform, finding good all-cause mortality and stroke outcomes in patients. At the same time, Germany-based Protembis has raised $30m in a Series B funding round to initiate a pivotal clinical trial of its intra-aortic filter device.